Skip to content
Review

Targeting the METTL5–MGST1 axis for cancer therapy: molecular mechanisms and therapeutic implications

Sep 2026 · Molecular Biology Reports · Vol 53 · 0 citations · 51 references
Medicine

TL;DR

This review comprehensively examines the structural biology, expression patterns, molecular mechanisms, and cancer-type-specific functions of both METTL5 and MGST1, with particular emphasis on their functional interdependence.

View source

Similar papers

Review Open access Sep 2026

The role and clinical impact of aberrant m6A RNA modification in cancer

This review systematically dissects how dysregulated m6A methylation fuels malignant transformation and progression by reinforcing core oncogenic hallmarks, sustained proliferation, metastasis, metabolic rewiring, and resistance to programmed cell death.

Sheng-Jie Tang, Rangping Xie, Jiang Fu et al. · 0 citations
Review Sep 2026

Lysine specific demethylase 5B promises to be a new focus of cancer drug-resistance: combination therapy.

Drug resistance remains a major obstacle to the long-term efficacy of cancer therapy. Lysine specific demethylase 5B (KDM5B), an epigenetic regulator of H3K4 methylation, has emerged as an important modulator of therapeutic resistance across multiple tumor contexts. In this review, we systematically summarize the mecha...

Ya-Quan Cao, Shu-Ya Li, Tian-Gui Wu et al. · 0 citations
Review Aug 2026

RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting

It is argued that while epitranscriptomics represents a compelling regulatory axis in cancer cell death, advancing the field will require integrative, high-resolution, and functionally precise approaches to move beyond correlative frameworks toward mechanistic and clinically actionable insights.

A. Mukherjee, Ankit Kumar Bharti, D. Mathew et al. · 0 citations
Open access Aug 2026

TRDMT1 slows lung cancer growth by stabilizing TFRC mRNA and triggering ferroptosis cell death

A novel TRDMT1-TFRC regulatory axis that suppresses LUAD progression through the modulation of ferroptosis is unveiled, highlighting this pathway as a promising therapeutic target for future interventions.

Ying Zhu, Zu-Li Jiang, You-Ming Chen et al. · 0 citations
Review Open access Aug 2026

m6A RNA methylation in breast cancer: from epitranscriptomic regulation to therapeutic targeting.

This review systematically summarize the functional roles of m6A regulators, including writers, erasers, and readers, in breast cancer biology and highlights the emerging clinical potential of m6A regulators as diagnostic and prognostic biomarkers, as well as therapeutic targets for overcoming drug resistance.

Zilong Chen, Chi Zhou, Zhuo-Run Song et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.